Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel cartilage repair therapy

11.04.2002


Diseases involving irremediable tissue damage of the musculoskeletal system account today for about 15% of hospital admissions in developed countries. With the ageing of the population, this is believed to gain significantly in importance in the coming years.



The majority of the disorders affecting the musculoskeletal system are the joint diseases, in particular osteoarthritis. The latter disease process is typically initiated and associated with defects of the articular cartilage and the underlying bone, causing pain as well as functional impairment. Early tissue repair resulting in the functional restoration of damaged joint surfaces is expected to prevent the development of osteoarthritis, and slow down the progression of the disease.

Different solutions and therapies are currently available for the local treatment of joint surface defects. Ranging from small-scaled arthroscopic debridement with microfracture or osteochondral grafting, to radical surgery involving total joint replacement by implantation of prosthesis. However, as the lifetime of joint prosthesis is limited, and with the ageing of the population, there is an increased need for more long lasting biological repair procedures.


Recent therapeutic approaches aim at repairing the articular cartilage by implantation of expanded cartilage cells. Cells used for the procedure are often autologous chondrocytes (i.e. a patient’s own cartilaginous cells), obtained from the patient`s involved joint via biopsy. Main difficulties with this technology include, amongst others, the so called “de-differentiation” of the cells which, during the in vitro expansion, loose their proper function i.e. the potential to form stable hyaline cartilage. The expanded cells instead can only make disorganized low quality fibro-cartilaginous tissue having different functional properties than the original articular cartilage covering the joints. Many existing therapeutic tissue regeneration methods therefore may lead to failure in mid- and long-term and, sometimes, may even aggravate the local damage.

TiGenix improves the Autologuous Chondrocyte Implantation procedure

The recently founded Belgian company TiGenix has been able to overcome this difficulty, unblocking herewith the way for successful and long-lasting tissue regeneration. Focusing on joint-surface defects and based on its own research, the company has been able to consistently grow the required hyaline-type cartilage in vivo. TiGenix has discovered specific molecular markers which are used to predict the ability of a cell population to form stable hyaline cartilage in vivo.

From these research findings, TiGenix has subsequently developed the cellular therapeutic product ChondroCelect®. ChondroCelect® is a proprietary technology using the patient`s own cells, resulting in a consistent and reproducible cell product, expected to improve the outcome of an autologous chondrocyte implantation procedure.
ChondroCelect® recently entered a prospective randomized clinical trial in 9 orthopedic centers in Belgium. The company actively prepares the extension of the trial to medical centers in other European countries. The commercial launch of ChondroCelect® is foreseen in 2004.

Therapies of next generation

The repair of chondral (cartilage) defects is the first application of TiGenix` research. The company has also identified specific markers that will enable the selection of adult multipotent precursor cells as the basis for next-generation tissue repair. The latter include therapeutic solutions for osteochondral (cartilage and underlying bone) defects and ultimately novel treatment options for osteoarthritis.

Who is TiGenix ?

TiGenix was founded in February 2000 as a spin-off of the University of Leuven (Belgium) by Frank Luyten, M.D., Ph.D., Professor at the Faculty of Medicine of the University of Leuven and Chairman of the Department of Rheumatology at the same university; and Ir. Gil Beyen, Partner at Arthur D. Little in Brussels and specialist in the healthcare sector.

TiGenix is a biomedical company with the mission of developing innovative products for successful repair and functional regeneration of damaged human tissue. The company aims at becoming one of the leading players in the field of musculoskeletal tissue engineering.

To do so, TiGenix is built on a multidisciplinary technology platform, combining expertise in cell and developmental biology, biomaterials and biosurgery. Various collaborations and strategic partnerships have been put in place to ensure the technological advancement and further developments of TiGenix, including with leading research centers, a bioinformatics company as well as Belgian and international experts as scientific advisors.

Currently Tigenix employs 20 people of which 11 are active in Research & Development. The new offices are located near the city of Leuven, while the company`s own GMP cell expansion facilities are located in the premises of the nearby Leuven University hospital center.

To date, TiGenix has been financed through seed capital, in a round led by Gemma Frisius Fund, and through technology grants from the Flemish government. To finance its further development and expansion strategy, the company is currently raising additional equity capital through a private placement.

Patrick Valkenberg | alphagalileo

More articles from Health and Medicine:

nachricht Inselspital: Fewer CT scans needed after cerebral bleeding
20.03.2019 | Universitätsspital Bern

nachricht Building blocks for new medications: the University of Graz is seeking a technology partner
19.03.2019 | Karl-Franzens-Universität Graz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The taming of the light screw

DESY and MPSD scientists create high-order harmonics from solids with controlled polarization states, taking advantage of both crystal symmetry and attosecond electronic dynamics. The newly demonstrated technique might find intriguing applications in petahertz electronics and for spectroscopic studies of novel quantum materials.

The nonlinear process of high-order harmonic generation (HHG) in gases is one of the cornerstones of attosecond science (an attosecond is a billionth of a...

Im Focus: Magnetic micro-boats

Nano- and microtechnology are promising candidates not only for medical applications such as drug delivery but also for the creation of little robots or flexible integrated sensors. Scientists from the Max Planck Institute for Polymer Research (MPI-P) have created magnetic microparticles, with a newly developed method, that could pave the way for building micro-motors or guiding drugs in the human body to a target, like a tumor. The preparation of such structures as well as their remote-control can be regulated using magnetic fields and therefore can find application in an array of domains.

The magnetic properties of a material control how this material responds to the presence of a magnetic field. Iron oxide is the main component of rust but also...

Im Focus: Self-healing coating made of corn starch makes small scratches disappear through heat

Due to the special arrangement of its molecules, a new coating made of corn starch is able to repair small scratches by itself through heat: The cross-linking via ring-shaped molecules makes the material mobile, so that it compensates for the scratches and these disappear again.

Superficial micro-scratches on the car body or on other high-gloss surfaces are harmless, but annoying. Especially in the luxury segment such surfaces are...

Im Focus: Stellar cartography

The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.

A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...

Im Focus: Heading towards a tsunami of light

Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.

"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Modelica Conference with 330 visitors from 21 countries at OTH Regensburg

11.03.2019 | Event News

Selection Completed: 580 Young Scientists from 88 Countries at the Lindau Nobel Laureate Meeting

01.03.2019 | Event News

LightMAT 2019 – 3rd International Conference on Light Materials – Science and Technology

28.02.2019 | Event News

 
Latest News

Solving the efficiency of Gram-negative bacteria

22.03.2019 | Life Sciences

Bacteria bide their time when antibiotics attack

22.03.2019 | Life Sciences

Open source software helps researchers extract key insights from huge sensor datasets

22.03.2019 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>